
Prostate cancer drug now available to more patients with aggressive form of disease
Fox News
A newly approved prostate cancer drug could bring new hope to patients with a common form of the disease. Novartis announced the FDA approval on March 28.
(RLTs are a form of targeted nuclear medicine that doctors use to treat multiple types of cancer, according to Novartis.) In clinical trials, Pluvicto "significantly reduced the risk of progression or death" by 59%. Melissa Rudy is senior health editor and a member of the lifestyle team at Fox News Digital. Story tips can be sent to melissa.rudy@fox.com.
The drug is intended for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have received one round of androgen receptor pathway inhibitors (ARPIs), a class of drugs used in the treatment of metastatic prostate cancer.